Please login to the form below

Not currently logged in
Email:
Password:

Roche and Evotec form biomarker alliance

Roche and Evotec are to collaborate on protein-activity based biomarkers for Roche's oncology drugs under development

Roche and Evotec, a drug discovery company specialising in development partnerships, are to collaborate on protein-activity based biomarkers for Roche's oncology drugs under development.

Evotec will employ its PhosphoScout platform to discover protein-phosphorylation's that predict favourable dosage and efficacy of targeted cancer drugs in patients. Roche will be responsible for conducting clinical trials, as well as assessing the development of companion diagnostics for patient stratification.

Mike Burgess, global head of oncology at Roche Pharma Research and Exploratory Development, said: "We are very pleased to collaborate with Evotec and benefit from the PhosphoScout technology to identify appropriate pharmacodynamics and patient stratification biomarkers. They are core to the development of targeted therapeutics for cancer therapy."

Under the initial three-year term Roche and Evotec will conduct multiple biomarker programmes for therapeutic antibodies or small molecule inhibitors.

27th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 women leaders in UK healthcare (part 3)
Part 3 of our list of thirty women leaders...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics